Affibody signs Letter of Intent with SHINE Technologies for supply of Lutetium-177

CAR-T Digest - August 2020

19 February 2026: Affibody signs Letter of Intent with SHINE Technologies for supply of Lutetium-177

Affibody announced that it has signed a Letter of Intent with SHINE Technologies to secure an additional supply source of non-carrier-added Lutetium-177, strengthening its radioligand therapy manufacturing and development capabilities
Under the agreement, SHINE will provide high-quality n.c.a. Lu-177 to support Affibody’s clinical research programs, including its lead candidate ABY-271, a HER2-targeted Lu-177–conjugated Affibody molecule currently being evaluated in a Phase 1 study for metastatic breast cancer
The supply arrangement is also intended to support other radioligand therapy assets emerging from Affibody’s proprietary technology platform, reinforcing long-term development plans across its pipeline
In addition to clinical supply, the parties may explore expanding the agreement to include commercial-scale Lu-177 supply for ABY-271 if the program advances successfully toward market approval
The collaboration marks a strategic step in securing reliable isotope access, which is critical for advancing radioligand therapies through clinical development and potential commercialization